PF-Atlas › Clinical Trials › NCT01684410
Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor , Hydrophobic Chromatography Process in Subjects With Cystic Fibrosis
Alpha-1 HC 100 mg · Phase 2
Registry ID
NCT01684410
Phase
Phase 2
Status
Completed
Drug / intervention
Alpha-1 HC 100 mg
Sponsor
Grifols Therapeutics LLC
Start
2012-08
Enrollment
30
Locations
6
About this trial
This was a randomized, double-blind, placebo-controlled, dose escalation study to assess the safety and tolerability of 100 mg and 200 mg of inhaled Alpha-1 HC administered once a day for three weeks in subjects aged 18 years and older with cystic fibrosis (CF). The treatment duration in this study was intended to provide multi-dose safety information prior to proceeding to longer durations of exposure.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT01684410 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.